Fenwick defended Oncothyreon and its directors in shareholder litigation based on alleged failure to disclose trial results. Our initial motion to dismiss was granted with prejudice and no appeal was taken. The Fenwick securities litigation team included partner Brian Buckley and associates Jeffrey Ware and Bradley Meissner.